The Board of Directors of the company in their meeting held on 23rd May, 2024 has inter alia considered and approved the following businesses: 1. Audited standalone and consolidated financial results for the fourth quarter as well as year ended 31.03.2024 along with the auditor report, statement of assets and liabilities, cash flow statement. 2. Declaration regarding unmodified opinion of the auditors on annual audited audited financial results. 3. Re- Appointment of Internal Auditor. 4. Re-Appointment of Secretarial Auditor. 5. Other routine business with the permission of the chair.

pdf

MediCaps Ltd.

15 May 2024, 03:48PM

39.11

-0.10%

Board Meeting

MEDI-CAPS LTD.-$ - 523144 - Board Meeting Intimation for 01/2024-25 Board Meeting Of The Company, Scheduled …

BSE India

MEDI-CAPS LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 ,inter alia, to consider and approve 1. The Standalone as well as Consolidated Audited Financial Results of the Company for the fourth quarter as well as financial year ended on 31st March, 2024 along with auditor's report thereon. 2. Other routine matters with the permission of chair.

pdf

MediCaps Ltd.

11 May 2024

39.11

-0.10%

Corp. Note

MEDI-CAPS LTD.-$ - 523144 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate …

BSE India

Intimation regarding issue of duplicate share certificate and stop transfer of shares as per enclosed letter.

pdf

MediCaps Ltd.

27 Apr 2024

39.11

-0.10%

Corp. Note

MEDI-CAPS LTD.-$ - 523144 - Format of the Initial Disclosure to be made by an entity …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyMEDI-CAPS LTD.- 2CIN NO.L70100MP1983PLC002231 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: ABHISHEK JAIN Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: Investors@medicaps.com Name of the Chief Financial Officer: Hemant sethi Designation: CHIEF FINANCIAL OFFICER EmailId: ACCOUNTS@MEDICAPS.COM Date: 27/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

MediCaps Ltd.

15 Apr 2024

39.11

-0.10%

Company Update

MEDI-CAPS LTD.-$ - 523144 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) …

BSE India

Pursuant to Regulation 40 (10) of SEBI (LODR) Regulation, 2015 , a certificate of compliance being annexed herewith issued by the PCS, under regulation 40 (9) of SEBI (LODR) Regulation, 2015 for the financial year ended 31.03.2024

pdf

MediCaps Ltd.

08 Apr 2024

39.11

-0.10%

Company Update

MEDI-CAPS LTD.-$ - 523144 - Compliance Certificate For The Year Ended On 31.03.2024 As Per Regulation …

BSE India

Pursuant to the regulation 7(3) of SEBI (LODR) Regulation 2015, a compliance certificate duly signed by Compliance officer of the company and RTA, for the financial year ended on 31.03.2024

pdf

MediCaps Ltd.

05 Apr 2024

39.11

-0.10%

Company Update

MEDI-CAPS LTD.-$ - 523144 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate for compliance of Regulation 74(5)of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended 31.03.2024

pdf

Is Medi-Caps Ltd. worth buying?

29 Votes:

Buy 55.17%

Sell 31.03%

Hold 13.79%